tetano
Editor, Senior Moderator
Pharmacol Res
. 2022 Jun 8;106293.
doi: 10.1016/j.phrs.2022.106293. Online ahead of print.
Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever
Francesca Marinelli[SUP] 1 [/SUP], Chiara Caporilli[SUP] 1 [/SUP], Annachiara Titolo[SUP] 1 [/SUP], Donato Rigante[SUP] 2 [/SUP], Susanna Esposito[SUP] 3 [/SUP]
Affiliations
Abstract
The innate immune system is critically involved in the pathogenesis of familial Mediterranean fever (FMF), characterized by dysregulated inflammasome activity and recurrent inflammatory attacks: this is the most common among monogenic autoinflammatory diseases, which shares some biochemical pathways with the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. In this short review we explore the overlap in the pathophysiology of FMF and SARS-CoV-2 infection, discussing how to understand better the interaction between the two diseases and optimize management. A poorer outcome of SARS-CoV-2 infection seems not to be present in infected FMF patients in terms of hospitalization time, need for oxygen support, need for intensive care, rate of complications and exitus. Long-term surveillance will confirm the relatively low risk of a worse prognosis observed so far in SARS-CoV-2-infected people with FMF. In these patients COVID-19 vaccines are recommended and their safety profile is expected to be similar to the general population.
Keywords: SARS-CoV-2 infection; autoinflammation; colchicine; familial Mediterranean fever; innovative biotechnologies; interleukin-1; personalized medicine.
. 2022 Jun 8;106293.
doi: 10.1016/j.phrs.2022.106293. Online ahead of print.
Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever
Francesca Marinelli[SUP] 1 [/SUP], Chiara Caporilli[SUP] 1 [/SUP], Annachiara Titolo[SUP] 1 [/SUP], Donato Rigante[SUP] 2 [/SUP], Susanna Esposito[SUP] 3 [/SUP]
Affiliations
- PMID: 35690330
- PMCID: PMC9181393
- DOI: 10.1016/j.phrs.2022.106293
Abstract
The innate immune system is critically involved in the pathogenesis of familial Mediterranean fever (FMF), characterized by dysregulated inflammasome activity and recurrent inflammatory attacks: this is the most common among monogenic autoinflammatory diseases, which shares some biochemical pathways with the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection. In this short review we explore the overlap in the pathophysiology of FMF and SARS-CoV-2 infection, discussing how to understand better the interaction between the two diseases and optimize management. A poorer outcome of SARS-CoV-2 infection seems not to be present in infected FMF patients in terms of hospitalization time, need for oxygen support, need for intensive care, rate of complications and exitus. Long-term surveillance will confirm the relatively low risk of a worse prognosis observed so far in SARS-CoV-2-infected people with FMF. In these patients COVID-19 vaccines are recommended and their safety profile is expected to be similar to the general population.
Keywords: SARS-CoV-2 infection; autoinflammation; colchicine; familial Mediterranean fever; innovative biotechnologies; interleukin-1; personalized medicine.